60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
April 03, 2024 07:58 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
March 14, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
February 20, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
January 30, 2024 09:00 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
January 16, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) announced that it has regained compliance with Nasdaq minimum listing requirements.
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
October 19, 2023 08:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma Presents Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual
Scientific Meeting
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
October 12, 2023 16:16 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma Suspends Phase IIB COVID Study, Pivots to Commercialization of Treatments for Malaria
and Tick-borne Illness
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
Management investor presentation webcast available Monday 9/11, 7:00 AM ETAttendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) --...
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
August 22, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine...
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
July 31, 2023 07:59 ET
|
Sixty Degrees Pharmaceuticals
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’...